Global Induced Pluripotent Stem Cells Production Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Induced Pluripotent Stem Cells Production Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Induced Pluripotent Stem Cells (iPSC) are generated from skin or blood cells that have been reprogrammed into an embryonic-like pluripotent state, allowing to produce an infinite source of any kind of human cell required for therapeutic reasons.
Induced Pluripotent Stem Cells Production report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Induced Pluripotent Stem Cells Production market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Academic Research and Drug Development are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Induced Pluripotent Stem Cells Production industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Induced Pluripotent Stem Cells Production key manufacturers include Lonza, Axol Bioscience Ltd., Evotec, Hitachi Ltd., Merck KGaA, REPROCELL Inc., Fate Therapeutics, Thermo Fisher Scientific, Inc. and StemCellFactory III, etc. Lonza, Axol Bioscience Ltd., Evotec are top 3 players and held % sales share in total in 2022.
Induced Pluripotent Stem Cells Production can be divided into Hepatocytes, Fibroblasts, Keratinocytes and Amniotic Cells, etc. Hepatocytes is the mainstream product in the market, accounting for % sales share globally in 2022.
Induced Pluripotent Stem Cells Production is widely used in various fields, such as Academic Research, Drug Development, Toxicity Screening and Regenerative Medicine, etc. Academic Research provides greatest supports to the Induced Pluripotent Stem Cells Production industry development. In 2022, global % sales of Induced Pluripotent Stem Cells Production went into Academic Research filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Induced Pluripotent Stem Cells Production market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Lonza
Axol Bioscience Ltd.
Evotec
Hitachi Ltd.
Merck KGaA
REPROCELL Inc.
Fate Therapeutics
Thermo Fisher Scientific, Inc.
StemCellFactory III
Applied StemCell Inc.
Segment by Type
Hepatocytes
Fibroblasts
Keratinocytes
Amniotic Cells
Others
Academic Research
Drug Development
Toxicity Screening
Regenerative Medicine
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Induced Pluripotent Stem Cells Production market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Induced Pluripotent Stem Cells Production, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Induced Pluripotent Stem Cells Production industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Induced Pluripotent Stem Cells Production in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Induced Pluripotent Stem Cells Production introduction, etc. Induced Pluripotent Stem Cells Production Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Induced Pluripotent Stem Cells Production market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Induced Pluripotent Stem Cells Production report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Induced Pluripotent Stem Cells Production market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Academic Research and Drug Development are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Induced Pluripotent Stem Cells Production industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Induced Pluripotent Stem Cells Production key manufacturers include Lonza, Axol Bioscience Ltd., Evotec, Hitachi Ltd., Merck KGaA, REPROCELL Inc., Fate Therapeutics, Thermo Fisher Scientific, Inc. and StemCellFactory III, etc. Lonza, Axol Bioscience Ltd., Evotec are top 3 players and held % sales share in total in 2022.
Induced Pluripotent Stem Cells Production can be divided into Hepatocytes, Fibroblasts, Keratinocytes and Amniotic Cells, etc. Hepatocytes is the mainstream product in the market, accounting for % sales share globally in 2022.
Induced Pluripotent Stem Cells Production is widely used in various fields, such as Academic Research, Drug Development, Toxicity Screening and Regenerative Medicine, etc. Academic Research provides greatest supports to the Induced Pluripotent Stem Cells Production industry development. In 2022, global % sales of Induced Pluripotent Stem Cells Production went into Academic Research filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Induced Pluripotent Stem Cells Production market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Lonza
Axol Bioscience Ltd.
Evotec
Hitachi Ltd.
Merck KGaA
REPROCELL Inc.
Fate Therapeutics
Thermo Fisher Scientific, Inc.
StemCellFactory III
Applied StemCell Inc.
Segment by Type
Hepatocytes
Fibroblasts
Keratinocytes
Amniotic Cells
Others
Segment by Application
Academic Research
Drug Development
Toxicity Screening
Regenerative Medicine
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Induced Pluripotent Stem Cells Production market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Induced Pluripotent Stem Cells Production, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Induced Pluripotent Stem Cells Production industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Induced Pluripotent Stem Cells Production in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Induced Pluripotent Stem Cells Production introduction, etc. Induced Pluripotent Stem Cells Production Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Induced Pluripotent Stem Cells Production market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices